Combination Products (Drug-Device): Complete FDA & EU MDR Regulatory Guide (2026)

Why Combination Products Are Reshaping Medical Device Regulation

A prefilled insulin syringe. A drug-eluting coronary stent. An autoinjector that delivers a GLP-1 receptor agonist for diabetes or weight management. A transdermal patch that releases fentanyl for chronic pain. These are not simply drugs, and they are not simply devices — they are combination products, and they represent one of the fastest-growing segments in healthcare.

The global drug-device combination products market is projected to reach $379.17 billion by 2030, growing from $243.02 billion in 2025 at a compound annual growth rate of 9.3%, according to MarketsandMarkets research published in May 2025. North America leads with 41% market share, followed by Europe at 28%. Injectable drug delivery devices — prefilled syringes, autoinjectors, and pen injectors — dominate the market, fueled by the rise of biologics and the growing demand for self-administration.

Yet for all their commercial promise, combination products create regulatory complexity that neither drug-only nor device-only manufacturers typically face. A single product may need to satisfy requirements from multiple regulatory frameworks simultaneously. The rules for determining which agency center reviews the product, which quality system applies, and how post-market reporting works are all different from standalone drugs or devices.

This guide explains the complete regulatory framework for drug-device combination products in both the United States (FDA) and European Union (EU MDR), with specific attention to the changes taking effect in 2026.

What Is a Combination Product?

FDA Definition

Under 21 CFR 3.2(e), the FDA defines a combination product as a product that comprises either:

1. A combination of a drug and a device; a biological product and a device; a drug and a biological product; or a drug, device, and biological product — physically, chemically, or otherwise combined or co-packaged as a single entity
2. Two or more separate products packaged together in a single package or as a unit — for example, a drug vial packaged with a delivery device
3. A drug, device, or biological product packaged separately that, according to its investigational plan or proposed labeling, is intended for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended use
4. An investigational drug, device, or biological product packaged separately that, according to its proposed labeling, is intended for use only with another individually specified investigational drug, device, or biological product

Common Examples of Drug-Device Combination Products

Product Type	Examples	Primary Mode of Action
Prefilled syringes	Insulin prefilled syringes, vaccine prefilled syringes, epinephrine autoinjectors	Drug (delivery device is secondary)
Autoinjectors	GLP-1 autoinjectors (Ozempic, Wegovy), epinephrine autoinjectors (EpiPen)	Drug
Drug-eluting stents	Coronary drug-eluting stents (Cypher, Taxus, Resolute)	Device (drug coating is secondary)
Transdermal patches	Fentanyl patches, nicotine patches, hormonal patches	Drug
Metered-dose inhalers	Albuterol inhalers, corticosteroid inhalers	Drug
Antibiotic bone cement	PMMA bone cement with gentamicin or vancomycin	Device
On-body delivery systems	Wearable injectors for biologics (e.g., Neulasta Onpro)	Drug
Drug-eluting contact lenses	Antihistamine-eluting contact lenses (Johnson & Johnson Acuvue Theravision)	Device
Pen injectors	Insulin pens, growth hormone pens	Drug

The Critical Distinction: Primary Mode of Action (PMOA)

The single most important regulatory determination for a combination product is its Primary Mode of Action (PMOA) — defined in 21 CFR 3.2(m) as "the single mode of action of a combination product that provides the most important therapeutic action of the combination product."

This determination dictates:

• Which FDA center leads the review (CDER for drug-led, CDRH for device-led, CBER for biologic-led)
• Which marketing pathway applies (NDA/ANDA vs. 510(k)/PMA vs. BLA)
• Which quality system requirements apply

FDA Regulatory Framework for Combination Products

The Office of Combination Products (OCP)

The FDA's Office of Combination Products (OCP), located within the Office of the Commissioner, is responsible for:

• Assigning combination products to the appropriate FDA center (CDER, CDRH, or CBER)
• Ensuring consistency and fairness in the regulation of combination products
• Resolving disputes between FDA centers regarding product jurisdiction

Request for Designation (RFD) Process

When it is unclear which FDA center should regulate a combination product, the sponsor can submit a Request for Designation (RFD) to the OCP. The RFD process is governed by 21 CFR Part 3.

How the RFD process works:

1. Submit the RFD — A written submission (no more than 15 pages) describing the product, its proposed indications, all known modes of action, and a recommended lead center with supporting rationale
2. OCP review — The OCP evaluates the submission, considers all modes of action, and determines the PMOA
3. 60-day deadline — The FDA must issue a designation letter within 60 calendar days. If no letter is issued within 60 days, the sponsor's recommended designation automatically takes effect
4. Binding determination — The designation letter constitutes an agency determination and can only be changed by requesting reconsideration within 15 calendar days

Pre-RFD option: If the sponsor lacks detailed product data, a Pre-Request for Designation (Pre-RFD) can be submitted to obtain non-binding informal feedback from the OCP. The Pre-RFD requires only a product description, proposed use or indications, and a description of how the product achieves its intended effects.

Marketing Pathways by Lead Center

Lead Center	Marketing Pathway	Typical Products
CDER (drug-led)	NDA (505(b)(2)), ANDA	Prefilled syringes, autoinjectors, transdermal patches
CDRH (device-led)	510(k), De Novo, PMA	Drug-eluting stents, antibiotic bone cement, drug-eluting contact lenses
CBER (biologic-led)	BLA 351(a)	Prefilled biologic syringes, on-body delivery systems for biologics

Even when one center leads, consulting reviewers from the other center(s) are routinely involved. A drug-led combination product reviewed by CDER will typically have device reviewers from CDRH assess the device constituent part, and vice versa.

CGMP Requirements: 21 CFR Part 4

Combination products must comply with all applicable current Good Manufacturing Practice (CGMP) requirements for each constituent part. For drug-device combinations, this means both:

• Drug CGMPs: 21 CFR Parts 210 and 211
• Device CGMPs: 21 CFR Part 820 (now the QMSR, effective February 2, 2026)

21 CFR Part 4 provides a streamlined compliance option: manufacturers of single-entity or co-packaged drug-device combination products can demonstrate compliance with either the drug CGMPs or the device quality system requirements, plus specific additional provisions from the other framework.

Streamlined Approach for Drug Manufacturers

If the manufacturer's quality foundation is drug CGMPs (21 CFR Parts 210/211), they must also comply with these specific device provisions:

• 21 CFR 820.20: Management responsibility
• 21 CFR 820.30: Design controls
• 21 CFR 820.50: Purchasing controls
• 21 CFR 820.100: Corrective and preventive action (CAPA)
• 21 CFR 820.170: Installation
• 21 CFR 820.200: Servicing

Streamlined Approach for Device Manufacturers

If the manufacturer's quality foundation is the device quality system (21 CFR Part 820 / QMSR), they must also comply with specific drug CGMP provisions from 21 CFR Parts 210/211 covering:

• Drug-specific production and process controls
• Drug-specific laboratory controls
• Drug-specific packaging and labeling controls
• Drug-specific holding and distribution requirements

QMSR Impact on Combination Products (2026)

The FDA's Quality Management System Regulation (QMSR), effective February 2, 2026, replaced the former Quality System Regulation (QSR) by incorporating ISO 13485:2016 by reference. This has significant implications for combination products:

• Updated 21 CFR Part 4: FDA made conforming edits to Part 4 to align with the QMSR. The streamlined approach still applies, but the device component now references ISO 13485:2016 requirements rather than the old QSR provisions
• Updated inspection program: The FDA issued Compliance Program Manual CP 7382.850, replacing the QSIT inspection technique with ISO 13485-aligned inspection methods
• Combination product inspections: Inspectors will now evaluate whether the manufacturer's quality system satisfies both the drug CGMP requirements and the ISO 13485-aligned QMSR requirements

Post-Market Safety Reporting

Post-market safety reporting for combination products depends on the marketing authorization pathway:

Marketing Pathway	Reporting Requirements
Device application (510(k), PMA)	21 CFR Parts 803 (MDR) and 806 (Corrections and Removals)
Drug application (NDA, ANDA)	21 CFR Part 314 (Field Alert Reports, Annual Reports)
BLA	21 CFR Parts 600 and 606

EU Regulatory Framework for Drug-Device Combination Products

The EU framework for drug-device combination products is fundamentally different from the US approach. Rather than a single "combination product" designation, the EU distinguishes between several categories based on the integration level between drug and device.

Categories Under EU Law

1. Integral Drug-Device Combinations (IDDCs) — Article 1(9) MDR

When a device and medicinal product form a single integral product that is intended exclusively for use in the given combination and is not reusable, it is regulated as a medicinal product under Directive 2001/83/EC.

Examples: Prefilled syringes, autoinjector pens, pressurized metered-dose inhalers

The key principle: the medicinal product has the principal action, and the device is intended to administer the medicinal product.

2. Co-Packaged Products

A drug and device supplied together as separate items (e.g., a vial of insulin with a reusable injection pen) fall under both the medicinal product regulations and the medical device regulations. The device component must independently comply with MDR requirements.

3. Devices That Incorporate a Substance — MDR Classification Rule 14

If a device incorporates a substance as an integral part (where the substance, if used separately, would be a medicinal product), and the substance has action ancillary to that of the device, the product is regulated as a medical device under the MDR but is classified in Class III (highest risk).

Examples: Drug-eluting stents, antibiotic bone cement, heparin-coated catheters

4. Substance-Based Devices — MDR Classification Rule 21

Devices composed of substances or combinations of substances that are introduced into or applied to the human body (and not absorbed) are classified based on their invasiveness and site of application. This is a new category introduced by the MDR.

MDR Article 117: Notified Body Opinion (NBOp)

One of the most significant changes introduced by the EU MDR for drug-device combination products is Article 117, which requires a Notified Body Opinion (NBOp) for integral drug-device combinations.

When Is an NBOp Required?

An NBOp is required when the device component of an integral drug-device combination falls into device risk classes Is, Im, IIa, IIb, or III. This includes:

• Sterile prefilled syringes (Class Is — sterile)
• Prefilled syringes with graduation marks (Class IIa or III depending on features)
• Autoinjectors with dose-measuring functions
• Inhaler devices with dose-counting mechanisms

A plain, non-sterile syringe without measurement features (Class I) does not require an NBOp.

The NBOp Process

1. Select a Notified Body — The marketing authorization applicant (MAA) selects a Notified Body designated under the MDR
2. Submit device technical documentation — The manufacturer provides evidence that the device component meets relevant General Safety and Performance Requirements (GSPRs) of the MDR
3. NB conducts assessment — The Notified Body evaluates the device constituent against applicable GSPRs and issues an NBOp
4. NBOp is binding on CHMP — The Committee for Medicinal Products for Human Use (CHMP) at EMA cannot bypass the NB Opinion. If the NBOp identifies deficiencies, the applicant must resolve them with the NB before CHMP can proceed
5. Timeline: NBOp processes typically take 2–6 months, making early engagement with a Notified Body essential

EMA Quality Requirements for Drug-Device Combinations

The European Medicines Agency has published a draft guideline on quality requirements for drug-device combinations that specifies:

• Device characterization: Physical and functional description of the device component, including materials, dimensions, and performance specifications
• Compatibility testing: Demonstrating compatibility between the drug substance and device materials (extractables, leachables, adsorption studies)
• Dose delivery performance: Reproducibility of dose delivery from the device (aligned with ICH M4Q 3.2.P.2.4)
• Functional testing: Device functionality under real-world conditions (e.g., injection force, needle insertion, dose accuracy)
• Stability considerations: Device functionality testing throughout the drug product's shelf life

Practical Challenges in the EU

The EU regulatory landscape for combination products presents several practical challenges:

• Device classification inconsistencies: Similar prefilled syringes may be classified as Class I, Is, IIa, or III by different manufacturers or MAAs, leading to different NB involvement requirements
• Economic operator roles: The MDR defines roles for manufacturers, authorized representatives, importers, and distributors. For drug-device combinations, these roles may not align neatly with medicinal product supply chain roles
• Lifecycle management: Changes to the device component of an integral DDC may require both a variation to the marketing authorization (drug side) and a reassessment by the Notified Body (device side)
• Add-on smart devices: When a connected app or smart device is added to an existing integral DDC, it creates regulatory questions about whether the add-on itself constitutes a medical device and whether it triggers new conformity assessment requirements

Comparison: FDA vs. EU Approach

Aspect	FDA (United States)	EU (MDR)
Classification	Single "combination product" category with PMOA determining lead center	Multiple categories: IDDCs, co-packaged, devices incorporating substances, substance-based devices
Jurisdiction determination	OCP assigns lead center (CDER, CDRH, CBER) via PMOA	Determined by principal action: drug-led (medicinal product law) vs. device-led (MDR)
Formal designation	RFD/Pre-RFD process available	No formal designation process; classification follows EU guidance
Quality system	21 CFR Part 4 streamlined approach (drug CGMPs or device QMSR + specific additions)	Separate but overlapping: GMP for drugs, ISO 13485/QMSR for devices
Device assessment for drug-led products	Consulting CDRH reviewers within FDA	Independent Notified Body Opinion (NBOp)
Post-market reporting	Depends on lead center pathway	Separate obligations under medicinal product and MDR frameworks

Development Strategy: Planning Your Combination Product

Early Regulatory Planning

Combination product regulation rewards early planning. Key steps include:

1. Determine the PMOA early — Before investing in development, understand which regulatory framework will dominate. A drug-eluting stent (device-led) has a fundamentally different pathway than a prefilled syringe (drug-led)

2. File a Pre-RFD or RFD (US) — If classification is uncertain, engage the OCP early. The Pre-RFD process provides non-binding feedback without committing to a full RFD

3. Engage a Notified Body early (EU) — Given the 2–6 month NBOp timeline, begin NB engagement during development, not at the time of marketing authorization filing

4. Build a unified quality system — Rather than maintaining separate drug and device quality systems, design a single system that satisfies both sets of requirements from the start. The 21 CFR Part 4 streamlined approach is designed to make this possible

Key Technical Considerations

Consideration	What to Address
Drug-device compatibility	Extractables and leachables studies, adsorption/absorption of drug by device materials, drug stability in contact with device components
Dose delivery accuracy	Demonstrating that the device consistently delivers the intended dose within defined tolerances
Human factors / usability	Combination products often require human factors validation testing per FDA guidance and IEC 62366-1. The FDA has separate guidance for human factors engineering of combination products
Combination-specific testing	Functional testing of the combined product (e.g., injection force, needle insertion, dose accuracy, drug release profile)
Stability	Drug stability in the device configuration, including device functionality testing at stability time points
Cybersecurity (for connected devices)	For smart injectors, connected autoinjectors, or digital health-enabled combination products, cybersecurity requirements under FDA Section 524B and the EU AI Act may apply

Regulatory Timelines and Costs

FDA

Factor	Typical Range
RFD processing	60 days (statutory)
Drug-led (NDA/ANDA)	10–12 months (standard review)
Device-led (510(k))	90 days (FDA review) + preparation time
Device-led (PMA)	180–360 days
Total development to approval	2–5 years depending on complexity
Consulting/regulatory costs	$200K–$2M+ depending on pathway and complexity

EU

Factor	Typical Range
NBOp process	2–6 months
Centralised Procedure (MAA)	210 days (active review) + clock stops
Device conformity assessment	6–18 months (depending on NB capacity)
Total time to market	2–5 years including device assessment
NB fees for NBOp	EUR 15,000–80,000 depending on device class and complexity

Common Pitfalls and How to Avoid Them

1. Assuming the product is "just a drug" or "just a device": The most common mistake is failing to recognize combination product classification. A prefilled syringe is not simply a drug in a container — the container is a medical device with its own regulatory requirements.

2. Late engagement with the OCP or Notified Body: Waiting until the marketing submission to clarify jurisdiction or obtain an NBOp adds months to the timeline. Engage early.

3. Inadequate drug-device compatibility data: Regulators increasingly expect robust extractables, leachables, and drug-device interaction studies. Incomplete data is a common cause of review delays.

4. Separate quality systems: Maintaining separate drug and device quality systems for a combination product creates unnecessary complexity and potential compliance gaps. Design a unified system.

5. Overlooking human factors: Combination products that patients use at home (autoinjectors, pens, inhalers) almost always require human factors validation testing. The FDA has specific guidance for human factors engineering of combination products.

6. Underestimating the NBOp timeline (EU): The NBOp is binding on CHMP. If the NB identifies deficiencies, they must be resolved before the marketing authorization can proceed. Budget adequate time.

Frequently Asked Questions

Is a drug-eluting stent a drug or a device?

Under FDA regulations, a drug-eluting stent is typically regulated as a device because the device (the stent) provides the primary mode of action — the stent mechanically props open the artery, while the drug coating is ancillary (preventing restenosis). Under the EU MDR, it falls under Classification Rule 14 (devices incorporating a substance) and is classified as Class III.

Do I need both drug and device CGMPs for a combination product?

Yes, but 21 CFR Part 4 allows a streamlined approach: you can comply with one complete set of CGMPs (either drug or device) plus specific additional provisions from the other. After the QMSR took effect on February 2, 2026, the device component now references ISO 13485:2016-aligned requirements.

What is the difference between the RFD and Pre-RFD?

An RFD is a formal, binding submission that results in a designation letter from the FDA within 60 days. A Pre-RFD is an informal, non-binding request for feedback from the OCP. Use a Pre-RFD when you need guidance but lack detailed product data; use an RFD when you need a definitive jurisdictional determination.

Does a prefilled syringe need a Notified Body Opinion in the EU?

It depends on the device classification. A sterile prefilled syringe or one with graduation marks (Class Is, IIa, or III) requires an NBOp. A plain, non-sterile syringe without measurement features (Class I) does not.

How does the QMSR affect combination product manufacturers?

The QMSR, effective February 2, 2026, replaced the QSR with ISO 13485:2016-aligned requirements. For combination product manufacturers, the streamlined approach under 21 CFR Part 4 still applies, but the device quality system component now references ISO 13485 requirements. FDA inspections under CP 7382.850 now follow ISO 13485-aligned methods.

Key Takeaways

• Combination products are one of the fastest-growing segments in healthcare, with the market projected to reach $379.17 billion by 2030
• In the US, the OCP determines regulatory jurisdiction based on the Primary Mode of Action (PMOA), and the RFD process provides a formal mechanism for classification
• In the EU, MDR Article 117 requires a Notified Body Opinion for drug-device combinations where the device component is Class Is or higher
• 21 CFR Part 4 provides a streamlined CGMP approach that allows compliance with either drug or device quality system requirements, plus specific additions
• The 2026 QMSR transition affects combination product manufacturers by aligning device quality system requirements with ISO 13485:2016
• Early regulatory planning, including Pre-RFD submissions (US) and early NB engagement (EU), is essential for efficient market access